CHARLOTTE, N.C., March 29, 2005 (PRIMEZONE) -- SmallCapReview.com ( www.SmallCapReview.com ), a leading small-cap stock information site, introduces BioCurex (Pink Sheets:BOCX) to its database of subscribers and its website audience.
Abbott and BioCurex today announced they have entered into a licensing agreement for BioCurex's RECAF(TM) material and technology. The receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
For more about BioCurex please visit http://www.smallcapreview.com/bocx.htm or the company's website at http://www.biocurex.com
SmallCapReview.com news is a Free Newsletter sent to subscribers, highlighting select small-cap stocks. To sign-up visit http://www.smallcapreview.com/subscribe.htm.
Forward Looking Statements
Except for the historical information contained herein, the matters discussed in this release include certain forward-looking statements, which are intended to be covered by safe harbors. Investors are cautioned that all forward-looking statements involve risks and uncertainties including, without limitation, the factors detailed from time to time in company filings with the Securities and Exchange Commission. These factors could affect businesses and financial results in the future and could cause actual results to differ materially from plans and projections. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the company or any other person that objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available. We assume no obligation to update any forward-looking statements, except as required by law.
Disclosure: No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SmallCapReview.com will disclose in its disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on our web site. SmallCapReview.com has been compensated eight thousand five hundred dollars by a third party for its efforts in presenting the BioCurex profile on its web site and distributing it to its database of subscribers, this creates an inherent conflict of interest and readers are encouraged to view the full disclaimer at www.smallcapreview.com/bocx.htm.